XENE
NASDAQXenon Pharmaceuticals Inc.
Price$33.49-0.34 (-0.99%)
01:30 PM07:45 PM
News · 26 weeks570%
2026-04-192026-10-11
Mix2390d
- Other11(48%)
- Insider6(26%)
- Earnings2(9%)
- SEC Filings2(9%)
- Analyst2(9%)
Latest news
25 items- INSIDERSEC Form 4 filed by Xenon Pharmaceuticals Inc.4 - Xenon Pharmaceuticals Inc. (0001582313) (Issuer)
- PRWolf Popper LLP Continues Investigation on Behalf of Xenon Pharmaceuticals Inc. InvestorsNEW YORK, Oct. 07, 2026 (GLOBE NEWSWIRE) -- Wolf Popper LLP continues to investigate potential claims on behalf of purchasers of Xenon Pharmaceuticals Inc. ("Xenon") common stock (NASDAQ:XENE). Xenon is a clinical-stage drug company developing azetukalner (formerly XEN1101), its lead drug candidate, for neurological and psychiatric disorders, principally focal-onset seizures, major depressive disorder (MDD), and bipolar depression. Azetukalner is a selective Kv7 potassium-channel opener designed to reduce excessive neuronal activity in the brain. In January 2025, Xenon announced the initiation of its Phase 3 X-NOVA2 trial, designed to enroll approximately 450 patients to evaluate a 20-mg
- ANALYSTGuggenheim resumed coverage on Xenon Pharmaceuticals with a new price targetGuggenheim resumed coverage of Xenon Pharmaceuticals with a rating of Buy and set a new price target of $73.00
- PRXenon Pharmaceuticals Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)VANCOUVER, BC and BOSTON, MA, Oct. 02, 2026 (GLOBE NEWSWIRE) -- Xenon Pharmaceuticals Inc. (NASDAQ:XENE), a neuroscience-focused biopharmaceutical company dedicated to drug discovery, clinical development, and commercialization of life-changing therapeutics for patients in need, today announced equity inducement grants to eight new non-officer employees consisting of an aggregate of 17,850 share options and 10,500 restricted share units (RSUs). All of the foregoing share options and RSUs were approved by the Compensation Committee of the Company’s Board of Directors with an effective date of October 1, 2026 and were granted as inducements material to the employees entering into employment
- INSIDERChief Financial Officer Kelly Thomas Patrick bought $559,740 worth of shares (15,000 units at $37.32) (SEC Form 4)4 - Xenon Pharmaceuticals Inc. (0001582313) (Issuer)
- INSIDERPRESIDENT & CEO Mortimer Ian bought $1,121,400 worth of shares (30,000 units at $37.38), increasing direct ownership by 151% to 49,923 units (SEC Form 4)4 - Xenon Pharmaceuticals Inc. (0001582313) (Issuer)
- PRXenon to Present at TD Cowen Novel Mechanisms in Neuropsychiatry & Epilepsy SummitVANCOUVER, BC and BOSTON, MA, Sept. 21, 2026 (GLOBE NEWSWIRE) -- Xenon Pharmaceuticals Inc. (NASDAQ:XENE), a neuroscience-focused biopharmaceutical company dedicated to drug discovery, clinical development and commercialization of life-changing therapeutics for patients in need, today announced that the company will present at an upcoming investor conference: TD Cowen Novel Mechanisms in Neuropsychiatry & Epilepsy Summit, Virtual Fireside Chat: Wednesday, September 23, 2:00–2:25 pm ET Details about the presentation, including webcast information, can be found on the Investors section of Xenon's website. When available, webcasts are posted for replay following the event. The above-listed
- ANALYSTXenon Pharmaceuticals downgraded by Deutsche Bank with a new price targetDeutsche Bank downgraded Xenon Pharmaceuticals from Buy to Hold and set a new price target of $46.00
- PRXenon Announces Azetukalner NDA Submission to FDA for Focal Seizures and Provides Update on Psychiatry Clinical ProgramNew Drug Application for azetukalner in focal seizures submitted to U.S. Food and Drug Administration; X-TOLE3 and X-ACKT continue to enroll focal seizure and PGTCS patients, respectively Enrollment in X-NOVA2 study in MDD completed with approximately 360 total patients; topline data readout expected Q1 2027 The Company has voluntarily initiated a temporary pause of enrollment of new patients in ongoing psychiatry studies; patients currently enrolled in the ongoing studies remain activeConference call today at 4:30 pm ET VANCOUVER, BC and BOSTON, MA, Sept. 17, 2026 (GLOBE NEWSWIRE) -- Xenon Pharmaceuticals Inc. (NASDAQ:XENE), a neuroscience-focused biopharmaceutical company dedicated to
- INSIDERDirector Svoronos Dawn exercised 5,144 shares at a strike of $8.15, increasing direct ownership by 20% to 31,373 units (SEC Form 4)4 - Xenon Pharmaceuticals Inc. (0001582313) (Issuer)
- PRXenon to Present at Wells Fargo Healthcare ConferenceVANCOUVER, BC and BOSTON, MA, Sept. 03, 2026 (GLOBE NEWSWIRE) -- Xenon Pharmaceuticals Inc. (NASDAQ:XENE), a neuroscience-focused biopharmaceutical company dedicated to drug discovery, clinical development and commercialization of life-changing therapeutics for patients in need, today announced that the company will present at an upcoming investor conference: Wells Fargo Healthcare Conference, Boston, MAFireside Chat: Wednesday, September 9, 11:00–11:30 am ET Details about the presentation, including webcast information, can be found on the Investors section of Xenon's website. When available, webcasts are posted for replay following the event. The above-listed dates and times are subjec
- INSIDERChief Medical Officer Kenney Christopher John sold $425,829 worth of shares (7,068 units at $60.25) as part of a pre-agreed trading plan, decreasing direct ownership by 100% to 2 units (SEC Form 4) (for tax liability)4 - Xenon Pharmaceuticals Inc. (0001582313) (Issuer)
- PRXenon Pharmaceuticals Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)VANCOUVER, BC and BOSTON, MA, Aug. 28, 2026 (GLOBE NEWSWIRE) -- Xenon Pharmaceuticals Inc. (NASDAQ:XENE), a neuroscience-focused biopharmaceutical company dedicated to drug discovery, clinical development, and commercialization of life-changing therapeutics for patients in need, today announced equity inducement grants to five new non-officer employees consisting of an aggregate of 13,450 share options and 7,850 restricted share units (RSUs). All of the foregoing share options and RSUs were approved by the Compensation Committee of the Company’s Board of Directors with an effective date of August 27, 2026 and were granted as inducements material to the employees entering into employment wi
- PRXenon to Highlight Phase 3 X-TOLE2 Clinical Data and Rational Polytherapy Potential for Azetukalner at EEC 2026Six presentations planned, including encore oral presentation of topline X-TOLE2 efficacy and safety resultsNew poster will highlight the mechanistic characterization of azetukalner, including its potential additive effects when used with commonly prescribed ASMs VANCOUVER, BC and BOSTON, MA, Aug. 26, 2026 (GLOBE NEWSWIRE) -- Xenon Pharmaceuticals Inc. (NASDAQ:XENE), a neuroscience-focused biopharmaceutical company dedicated to drug discovery, clinical development, and commercialization of life-changing therapeutics for patients in need, today announced multiple data presentations at the upcoming 16th European Epilepsy Congress (EEC), taking place September 5-9, 2026, in Athens, Greece.
- INSIDERDirector Gannon Steven sold $640,550 worth of shares (10,000 units at $64.06), decreasing direct ownership by 84% to 1,870 units (SEC Form 4)4 - Xenon Pharmaceuticals Inc. (0001582313) (Issuer)
- SECAmendment: SEC Form SCHEDULE 13G/A filed by Xenon Pharmaceuticals Inc.SCHEDULE 13G/A - Xenon Pharmaceuticals Inc. (0001582313) (Subject)
- SECAmendment: SEC Form SCHEDULE 13G/A filed by Xenon Pharmaceuticals Inc.SCHEDULE 13G/A - Xenon Pharmaceuticals Inc. (0001582313) (Subject)
- SECSEC Form 10-Q filed by Xenon Pharmaceuticals Inc.10-Q - Xenon Pharmaceuticals Inc. (0001582313) (Filer)
- SECXenon Pharmaceuticals Inc. filed SEC Form 8-K: Results of Operations and Financial Condition, Regulation FD Disclosure, Financial Statements and Exhibits8-K - Xenon Pharmaceuticals Inc. (0001582313) (Filer)
- PRXenon Reports Q2 2026 Financial Results and Provides Business UpdateNDA submission for azetukalner on track for Q3 2026 following pre-NDA meeting with FDA Phase 3 X-TOLE3 study in FOS and X-ACKT study in PGTCS continue to enroll Three Phase 3 studies of azetukalner in neuropsychiatry continue to advance, with topline data from X-NOVA2 study in MDD expected H1 2027 Phase 1 studies of novel NaV1.7 (XEN1701) and KV7 (XEN1120) candidates expected to complete H2 2026; Phase 1 study underway for second NaV1.7 (XEN1720) candidate for painCash, cash equivalents and marketable securities of $1.2 billion with cash runway into 2029Conference call at 4:30 pm ET today VANCOUVER, BC and BOSTON, MA, Aug. 06, 2026 (GLOBE NEWSWIRE) -- Xenon Pharmaceuticals Inc. (NASDAQ:XE
- SECAmendment: SEC Form SCHEDULE 13G/A filed by Xenon Pharmaceuticals Inc.SCHEDULE 13G/A - Xenon Pharmaceuticals Inc. (0001582313) (Subject)
- PRXenon Pharmaceuticals Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)VANCOUVER, BC and BOSTON, MA, July 31, 2026 (GLOBE NEWSWIRE) -- Xenon Pharmaceuticals Inc. (NASDAQ:XENE), a neuroscience-focused biopharmaceutical company dedicated to drug discovery, clinical development, and commercialization of life-changing therapeutics for patients in need, today announced equity inducement grants to eleven new non-officer employees consisting of an aggregate of 32,758 share options and 19,013 restricted share units (RSUs). All of the foregoing share options and RSUs were approved by the Compensation Committee of the Company’s Board of Directors with an effective date of July 30, 2026 and were granted as inducements material to the employees entering into employment w
- PRXenon to Report Q2 2026 Financial Results on August 6, 2026VANCOUVER, BC and BOSTON, MA, July 30, 2026 (GLOBE NEWSWIRE) -- Xenon Pharmaceuticals Inc. (NASDAQ:XENE), a neuroscience-focused biopharmaceutical company dedicated to drug discovery, clinical development, and commercialization of life-changing therapeutics for patients in need, today announced it will report its second quarter 2026 financial results and provide a business update after the close of U.S. financial markets on Thursday, August 6, 2026. Company Presentation Details: Date:Thursday, August 6, 2026Time:4:30pm ET (1:30pm PT)Webcast:Pre-register hereDial-In: (800) 715-9871 toll-free or (646) 307-1963 for international callersConference ID:5286122 A live webcast of the compan
- PRXenon Pharmaceuticals Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)VANCOUVER, British Columbia and BOSTON, MA, July 02, 2026 (GLOBE NEWSWIRE) -- Xenon Pharmaceuticals Inc. (NASDAQ:XENE), a neuroscience-focused biopharmaceutical company dedicated to drug discovery, clinical development, and commercialization of life-changing therapeutics for patients in need, today announced equity inducement grants to four new non-officer employees consisting of an aggregate of 20,200 share options and 11,850 restricted share units (RSUs). All of the foregoing share options and RSUs were approved by the Compensation Committee of the Company’s Board of Directors with an effective date of July 1, 2026 and were granted as inducements material to the employees entering into e
- INSIDERDirector Patou Gary sold $70,251 worth of shares (1,322 units at $53.14) as part of a pre-agreed trading plan, decreasing direct ownership by 5% to 24,896 units (SEC Form 4) to cover withholding tax4 - Xenon Pharmaceuticals Inc. (0001582313) (Issuer)
XENE FAQ
7 questionsWhat does Xenon Pharmaceuticals Inc. do?
Xenon Pharmaceuticals Inc., a clinical-stage biopharmaceutical company, engages in developing therapeutics to treat patients with neurological disorders in Canada. Its clinical development pipeline includes XEN496, A Kv7 potassium channel modulator that is Phase III clinical trials for the treatment of KCNQ2 epilepsy encephalopathy; and XEN1101, A Kv7 potassium channel modulator, which is in Phase II clinical trial for the treatment of epilepsy and other neurological disorders. The company's product candidates also comprise NBI-921352, a selective Nav1.6 sodium channel inhibitor that is in...Where does XENE stock trade?
Xenon Pharmaceuticals Inc. (XENE) is listed on NASDAQ.What sector and industry is XENE in?
Xenon Pharmaceuticals Inc. operates in the Health Care sector, Biotechnology: Pharmaceutical Preparations industry.When did Xenon Pharmaceuticals Inc. go public?
Xenon Pharmaceuticals Inc. (XENE) completed its IPO in 2014.What are analysts saying about XENE?
Xenon Pharmaceuticals Inc. has had 8 recent analyst actions on file. The most recent action was from Guggenheim: Buy on 2026-10-06. Recent price targets range from $4600.00 to $4800.00.What companies are similar to XENE?
Notable peers in the same industry include LLY (Eli Lilly and Company), JNJ (Johnson & Johnson), ABBV (AbbVie Inc.), MRK (Merck & Company Inc.), NVS (Novartis AG). Compare XENE side-by-side with any of them on Quantisnow.How can I track XENE on Quantisnow?
Quantisnow aggregates Xenon Pharmaceuticals Inc.'s SEC filings, analyst ratings, insider transactions, FDA approvals, and press releases the moment they hit the wire (Wall Street's wire, on your screen.). Follow XENE to receive live email and push alerts on every new disclosure.